NCT06370845 ABUNDANCE of A NATURAL ODOUR in HUMAN CEREBROSPINAL FLUID AFTER OLFACTORY EXPOSURE - the OLFO-Brain Study
| NCT ID | NCT06370845 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Overweight and Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-04-14 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 32 participants in total. It began in 2026-04-14 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate the abundance of a natural odour in human cerebrospinal fluid in obese and lean participants after inhalation thereof. Participants will undergo blood sample collection and inhalation of either a natural odour or placebo through an inhaler in addition to a liquor puncture prescribed in standard of care context.
Eligibility Criteria
Inclusion Criteria Obese Participants: * Age 18-60 years * Written informed consent * Scheduled for routine liquor puncture * BMI ≥ 30 kg/m2 * No proven diagnose of diabetes Inclusion Criteria Lean Participants: * Age 18-60 years * Written informed consent * Scheduled for routine liquor puncture * BMI 18-25 kg/m2 Exclusion Criteria: * Known allergy to the natural odour * Acute upper respiratory tract infection, acute or chronic sinusitis * Present or past surgical intervention of the nasal cavity, the paranasal sinus, the pituitary or the frontal brain * Pregnancy/lactation * Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease, severe renal impairment with an estimated glomerular filtration rate \<30 ml/min/m2) * Inability to understand the study procedure and to sign the study consent
Contact & Investigator
Katharina Timper, Prof. Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital Basel, Department of Endocrinology, Diabetology and Metabolism
Frequently Asked Questions
Who can join the NCT06370845 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Overweight and Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06370845 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06370845 currently recruiting?
Yes, NCT06370845 is actively recruiting participants. Contact the research team at katharina.timper@usb.ch for enrollment information.
Where is the NCT06370845 trial being conducted?
This trial is being conducted at Basel, Switzerland, Basel, Switzerland.
Who is sponsoring the NCT06370845 clinical trial?
NCT06370845 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Katharina Timper, Prof. Dr. med. at University Hospital Basel, Department of Endocrinology, Diabetology and Metabolism. The trial plans to enroll 32 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.